ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 32

Regulation of Senescence and Inflammatory Mediators By N- and C-Terminal Parathyroid Hormone-Related Protein in Osteoarthritic Human Osteoblasts  

Maria Isabel Guillén1, Julia Platas1, Sergio Portal-Nuñez2, Pedro Esbrit3 and M.J. Alcaraz4, 1Pharmacology, University of Valencia, Burjasot, Valencia, Spain, 2Metabolismo mineral y óseo, Fundación Jimenez Diaz, Madrid, Spain, 3Fundación Jimenez Diaz, Madrid, Spain, 4University of Valencia, Burjasot, Valencia, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Inflammation, Osteoarthritis, osteoblasts and parathyroid hormone, Senescent Cells

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling

Session Type: Abstract Submissions (ACR)

Background/Purpose

In osteoarthritis (OA), there is an abnormal remodeling process in subchondral bone associated with an altered osteoblast metabolism. Inflammatory mediators participate in bone remodeling and cartilage degradation during OA progression. Parathyroid hormone (PTH) and its bone counterpart, PTH-related protein (PTHrP), increase bone turnover through interaction of their N-terminal domain with the PTH type 1 receptor in osteoblasts. PTHrP peptides may be a novel approach to treat bone metabolic alterations. The aim of this study was to investigate the effects of different PTHrP peptides, PTHrP (1-37), and the PTH-unrelated peptides, PTHrP (107-139) and PTHrP (107-111) (osteostatin), on osteoblast senescence and the production of inflammatory mediators and degradative enzymes in osteoarthritic human osteoblasts stimulated with interleukin-1β (IL-1β).

Methods

Osteoblasts were obtained from 8 patients undergoing total knee joint replacement. Subchondral bone tissue obtained from tibial plateau was minced into small portions and digested with collagenase under agitation. Collected tissue was seeded in osteogenic medium to obtain osteoblastic cells according to a standard procedure. At first passage, osteoblastic cells were treated with PTHrP (1-37), PTHrP (107-139) and osteostatin (each at 100 nM) with or without IL-1β (10 ng/ml) for 1, 3 and 6 days. Senescence-associated β-galactosidase activity (SA-β-Gal) was assessed by cytochemistry. mRNA expression of matrix metalloproteinases (MMPs) and senescence markers was determined by qPCR. Prostaglandin E2 (PGE2) was measured by RIA, pro-inflammatory cytokines by ELISA, and cyclooxygenase-2 (COX-2) expression was determined by immunocytochemistry.

Results

IL-1β increased senescence features and the secretion of inflammatory mediators in osteoarthritic osteoblasts. Increased production of cytokines, MMPs and PGE2 may contribute to bone sclerosis and degradative processes in the joint. The three PTHrP peptides tested significantly down-regulated SA-β-Gal and the expression of caveolin-1, p21, p53, MMP-1 and MMP-3. In addition, these peptides reduced the release of tumor necrosis factor-α into the culture medium. PGE2 production was significantly decreased by PTHrP (1-37) on days 1, 3 and 6, and also by each C-terminal PTHrP peptide on day 6. This effect on PGE2 was dependent on the downregulation of IL-1β-induced COX-2 overexpression.

Conclusion

These findings show that both N- and C-terminal PTHrP peptides counteract the effects of IL-1β on the induction of cell senescence and the production of inflammatory and degradative mediators in osteoarthritic human osteoblasts, suggesting a beneficial effect of these peptides in osteoarthritic subchondral bone.


Disclosure:

M. I. Guillén,
None;

J. Platas,
None;

S. Portal-Nuñez,
None;

P. Esbrit,
None;

M. J. Alcaraz,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regulation-of-senescence-and-inflammatory-mediators-by-n-and-c-terminal-parathyroid-hormone-related-protein-in-osteoarthritic-human-osteoblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology